Ny, the rotarod test, phenotyping, and cell culture experiments. M.E.D.-C. performed the morphological analyses. P.G.-G.

March 4, 2022

Ny, the rotarod test, phenotyping, and cell culture experiments. M.E.D.-C. performed the morphological analyses. P.G.-G. contributed to the (S)-Venlafaxine Serotonin Transporter mitochondrial assays, proteomics experiments, along with the management on the mouse colony. R.Z.C. supervised the proteomics experiments and analyses. D.A.-C. contributed to the discussions. L.C.L. conceived the idea for the project, supervised the experiments, and edited the manuscript. The results shown in this article constituted a section of A.H.-G.’s doctoral thesis at the University of Granada. All authors have study and agreed to the published version of the manuscript. Funding: This operate was supported by grants from Ministerio de Ciencia e Innovaci , Spain, plus the ERDF (grant number RTI2018-093503-B-100); in the Muscular Dystrophy Association (MDA602322); in the Junta de Andaluc (grant number P20_00134); in the University of Granada (grant reference “UNETE,” UCE-PP2017-06); and by EPIC-XS, project number 823839, funded by the Horizon 2020 system from the European Union. P.G.-G. is actually a “FPU fellow” from the Ministerio de Universidades, Spain. M.E.D.-C. is supported by the Muscular Dystrophy Association. E.B.-C. is supported by the Junta de Andaluc . A.H.-G. was partially supported by the “FPU program” and the research plan from the University of Granada. Information Availability Statement: The mass spectrometry proteomics data had been deposited for the ProteomeXchange (http://www.proteomexchange.org/ accessed on 1 April 2020). Consortium through the PRIDE companion repository with the dataset identifier PXD018311 (1 April 2020).Biomedicines 2021, 9,25 ofAcknowledgments: We thank Seth Joel Drey for the English editing. We are grateful to Ana Fernandez (Universidad de Granada) for her technical assistance in the facilities of bioanalysis. We thank members of your Heck Lab for their support in analyzing the proteomics samples. Conflicts of Interest: A.H.-G., M.E.D.-C., E.B.-C., P.G.-G. and L.C.L. are inventors around the patent application quantity P202031235.
biomedicinesArticleA Gadolinium DO3A Amide m-Phenyl Boronic Acid MRI Probe for Targeted Imaging of Sialated Strong TumorsChristu Rajan 1, , Jaya Seema 1, , Yu-Wen Chen 2 , Tsai-Chen Chen 1 , Ming-Huang Lin 1 , Chia-Huei Lin 1 and Dennis Wen-Han Hwang 1,two, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan; [email protected] (C.R.); [email protected] (J.S.); [email protected] (T.-C.C.); [email protected] (M.-H.L.); [email protected] (C.-H.L.) Biomedical Translation Investigation Center, Academia Sinica, Taipei 115, Taiwan; [email protected] Correspondence: [email protected] Those authors have been contributed equally.Abstract: We created a new probe, Gd-DO3A-Am-PBA, for imaging tumors. Our outcomes showed active targeting of Gd-DO3A-Am-PBA to sialic acid (SA) moieties, with elevated cellular Trilinolein Autophagy labeling in vitro and enhanced tumor accumulation and retention in vivo, in comparison to the commercial Gadovist. The effectiveness of our newly synthesized probe lies in its adequate retention phase, which is anticipated to provide a suitable time window for tumor diagnosis as well as a quicker renal clearance, which will decrease toxicity dangers when translated to clinics. Hence, this study is usually extended to other tumor sorts that express SA on their surface. Targeting and MR imaging of any sort of tumors can also be accomplished by conjugating the newly synthesized contrast agent with certain antibodies. This study therefore opens new.